Rituximab kills freshly isolated B-NHL and B-CLL more efficiently by complement than by ADCC in vitro. Role of CD20 expression levels and of the CD55 and CD59 complement inhibitors.

被引：0
|
作者：
Golay, J
Facchinetti, V
Gramigna, R
Lazzari, M
Dastoli, G
Barbui, T
Rambaldi, A
Introna, M
机构：
[1] Mario Negri Inst Pharmacol Res, Lab Mol Immunohaematol, I-20157 Milan, Italy
[2] Osped Riuniti Bergamo, Div Haematol, I-24100 Bergamo, Italy
[3] Roche Italia, Monza, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
633
引用
收藏
页码：150A / 150A
页数：1
相关论文
共 12 条
  • [1] The susceptibility of freshly isolated B-non Hodgkin lymphoma cells to Rituximab and complement is determined by CD20 levels and the CD55/CD59 inhibitors.
    Golay, J
    Lazzari, M
    Facchinetti, V
    Borleri, G
    Dastoli, G
    Barbui, T
    Introna, M
    Rambaldi, A
    [J]. BLOOD, 2000, 96 (11) : 338A - 338A
  • [2] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
    Golay, J
    Lazzari, M
    Facchinetti, V
    Bernasconi, S
    Borleri, G
    Barbui, T
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2001, 98 (12) : 3383 - 3389
  • [3] Rituximab induced apoptosis "in vitro" on binet a B-CLL; Correlation with CD59/CD20 expression.
    Sarsotti, E
    Terol, MJ
    Benet, I
    Martinez-Climent, JA
    Marugan, I
    Garcia-Conde, J
    [J]. BLOOD, 2003, 102 (11) : 861A - 861A
  • [4] Expression of complement inhibitors CD46, CD55 and CD59 and response to rituximab in patients with CD20+ non hodgkins lymphoma
    Dzietczenia, J.
    Wrobel, T.
    Mazur, G.
    Biedron, M.
    Jazwiec, B.
    Kuliczkowski, K.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 533 - 533
  • [5] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma
    Justyna Dzietczenia
    Tomasz Wróbel
    Grzegorz Mazur
    Rafał Poręba
    Bożena Jaźwiec
    Kazimierz Kuliczkowski
    [J]. Medical Oncology, 2010, 27 : 743 - 746
  • [6] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma
    Dzietczenia, Justyna
    Wrobel, Tomasz
    Mazur, Grzegorz
    Poreba, Rafal
    Jazwiec, Bozena
    Kuliczkowski, Kazimierz
    [J]. MEDICAL ONCOLOGY, 2010, 27 (03) : 743 - 746
  • [7] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    [J]. LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [8] Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy
    Bannerji, R
    Pearson, M
    Flinn, IW
    Shinn, CA
    Goodrich, A
    Lucas, M
    Byrd, JC
    [J]. BLOOD, 2000, 96 (11) : 164A - 164A
  • [9] Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis.
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Borleri, GM
    Tedesco, F
    Dastoli, G
    Barbui, T
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 1999, 94 (10) : 92A - 92A
  • [10] Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Lazzari, M
    Borleri, GM
    Bernasconi, S
    Tedesco, F
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2000, 95 (12) : 3900 - 3908
12